Pfenex and Alvogen will have to conduct further studies to convince the US Food and Drug Administration that their PF708 version of teriparatide is therapeutically equivalent to Eli Lilly’s Forteo brand, the agency has directed.
The FDA approved the hybrid 505(b)(2) new drug application for PF708, to be known as Bonsity, in October last year,...




